Immix Biopharma, Inc.Immix Biopharma, Inc.Immix Biopharma, Inc.

Immix Biopharma, Inc.

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪50.06 M‬USD
−0.88USD
‪−15.43 M‬USD
0.00USD
‪16.37 M‬
Beta (1Y)
2.94
Employees (FY)
17
Change (1Y)
+6 +54.55%
Revenue / Employee (1Y)
0.00USD
Net income / Employee (1Y)
‪−907.41 K‬USD

About Immix Biopharma, Inc.


CEO
Ilya Rachman
Headquarters
Los Angeles
Founded
2012
FIGI
BBG00HLCWH09
Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company was founded by Ilya Rachman, Sean Senn, and Vladimir Torchilin in 2012 and is headquartered in Los Angeles, CA.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of IMMX is 1.82 USD — it has increased by 7.06% in the past 24 hours. Watch Immix Biopharma, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Immix Biopharma, Inc. stocks are traded under the ticker IMMX.
IMMX stock has risen by 7.69% compared to the previous week, the month change is a 5.81% rise, over the last year Immix Biopharma, Inc. has showed a −58.35% decrease.
We've gathered analysts' opinions on Immix Biopharma, Inc. future price: according to them, IMMX price has a max estimate of 7.00 USD and a min estimate of 7.00 USD. Watch IMMX chart and read a more detailed Immix Biopharma, Inc. stock forecast: see what analysts think of Immix Biopharma, Inc. and suggest that you do with its stocks.
IMMX reached its all-time high on Jan 3, 2022 with the price of 8.68 USD, and its all-time low was 0.68 USD and was reached on Nov 10, 2022. View more price dynamics on IMMX chart.
See other stocks reaching their highest and lowest prices.
IMMX stock is 17.33% volatile and has beta coefficient of 2.94. Track Immix Biopharma, Inc. stock price on the chart and check out the list of the most volatile stocks — is Immix Biopharma, Inc. there?
Today Immix Biopharma, Inc. has the market capitalization of ‪49.96 M‬, it has increased by 8.28% over the last week.
Yes, you can track Immix Biopharma, Inc. financials in yearly and quarterly reports right on TradingView.
Immix Biopharma, Inc. is going to release the next earnings report on Feb 26, 2025. Keep track of upcoming events with our Earnings Calendar.
IMMX net income for the last quarter is ‪−7.15 M‬ USD, while the quarter before that showed ‪−4.39 M‬ USD of net income which accounts for −62.75% change. Track more Immix Biopharma, Inc. financial stats to get the full picture.
No, IMMX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 21, 2024, the company has 17.00 employees. See our rating of the largest employees — is Immix Biopharma, Inc. on this list?
Like other stocks, IMMX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Immix Biopharma, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Immix Biopharma, Inc. technincal analysis shows the buy rating today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Immix Biopharma, Inc. stock shows the sell signal. See more of Immix Biopharma, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.